Tag:
Sprycel
Latest Headlines
Latest Headlines
India to hit Roche, BMS with compulsory licenses on 3 cancer drugs
India is taking another swipe at Big Pharma. Three swipes, in fact: The government has started the process of granting three more compulsory licenses, this time on cancer treatments from Roche and Bristol-Myers Squibb. That means cheap copies of the on-patent drugs could soon hit the Indian market.
Pfizer nabs another targeted cancer drug OK from FDA
The FDA gave its blessing to Bosulif, a treatment for chronic myelogenous leukemia (CML) patients with Philadelphia chromosome-positive disease. It's a second-line approval, for patients who've failed on--or can't tolerate--another drug. Analysts figure the approval is worth $341 million in annual sales by 2016, Reuters reports.
Ariad's ponatinib scores well in key leukemia study
Ariad Pharmaceuticals' key cancer drug ponatinib didn't disappoint at the ASCO meeting, with new data from the company's pivotal "PACE" trial trumping those revealed late last year.
BMS delivers sales, profit growth in Plavix's final quarter
All eyes are on new and forthcoming drugs as Bristol-Myers Squibb reports a 12% increase in first-quarter profits.
Bristol-Myers' Q4 shows growth in newer products
Bristol-Myers Squibb's ( $BMY ) earnings didn't reach the Wall Street goalposts, partly because of higher costs, some of them attributed to U.S. healthcare reforms. Sales of its flagship drug,...
It's final: Tasigna in, Sprycel out in NICE guidelines
The National Institute for Health and Clinical Excellence has struck again. Despite two appeals of its draft recommendations, the agency let in only one new drug for chronic myeloid leukemia.
NICE says nay to Sprycel, yea to discounted Tasigna
The U.K.'s cost-effectiveness watchdog rejected Bristol-Myers Squibb's ( $BMY ) Sprycel for chronic myeloid leukemia, but accepted Novartis' ( $NVS ) Glivec and its follow-up drug Tasigna after the Swiss
FDA adds warning to BMS leukemia drug
Bristol-Myers Squibb's ( $BMY ) leukemia treatment Sprycel has a new warning. In a new safety announcement, the FDA said the drug can increase the risk of pulmonary arterial hypertension (PAH). The
Will Gleevec, Sprycel researchers get a call from Stockholm?
Scientists who worked on the targeted leukemia drugs Gleevec and Sprycel may be in line for the Nobel Prize this year, a prize-prediction expert says. The drugs, sold by Novartis ( $NVS ) and
Data aids Novartis push to replace Gleevec with Tasigna
What does a drugmaker do when a huge drug is edging toward that patent cliff? It pushes another branded med as a replacement for that soon-to-go-generic treatment--and crosses its fingers in hopes
